Portfolio articles – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

Maximizing value when developing oncolytic viral therapy

2025.04.012025.04.30 / As the new CEO for Theolytics, David Apelian aims to take full advantage of the first clinical studies for the company’s lead product. The UK-based biotech has a whole potential platform for creating ...

Applying the best of both science and business to treat heart failure

2025.01.312025.04.30 / AnaCardio is focused on bringing treatment for one of today’s largest unmet medical needs to market. According to CEO Patrik Strömberg, the Swedish biopharmaceutical company is leveraging strong scie ...

Navigating the journey of orphan drug development

2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...

Johan Kördel Ph.D., Managing Partner - Sound Bioventures

Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage

2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...

Evolving to the next phase of viral therapy development

2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...

Bringing everything together for an autoimmunity game changer

2023.09.202024.05.13 / At AbolerIS Pharma, it's all about creating balance. The Belgian/French biotech company is gearing up for clinical trials of a novel therapy for stabilizing chaotic immune systems. As CEO Ann Meulema ...

Reaching the next level of creating novel therapies for genetic diseases

2023.05.312024.05.13 / ARTHEx Biotech is entering a new phase in its development of breakthrough treatments for genetically-driven disorders. It’s set to begin the first clinical trials for one of its microRNA modulators a ...

The drive to adapt a lab discovery into treatment of neurodegeneration

2023.03.292024.05.13 / Teitur Trophics is breaking new ground when it comes to neurodegenerative diseases. After identifying a previously unknown means of preserving functioning brain cells, the biotech company’s founders ...

Brey Therapeutics

A visionary journey to innovate sight-preserving therapies

2023.01.252024.05.13 / Breye Therapeutics is all about the people. Whether it’s the company’s team or the patients whose eyesight they seek to protect, the focus is consistently on the human factor. It’s a value influenced ...